Critical Care

official impact factor 4.60
Search for
Advanced search
Critical Care
Tools

Clinical review: Drotrecogin alfa (activated) as adjunctive therapy for severe sepsis – practical aspects at the bedside and patient identification

Pierre-François Laterre* and Xavier Wittebole

Critical Care 2003, 7:445-450 doi:10.1186/cc2342

Accesses  

  • Last 30 days: 49 accesses
  • Last year: 965 accesses
  • All time: 11188 accesses

Cited by

BioMed Central: 3 citations

Research   Open Access Highly Accessed

Early drotrecogin alpha (activated) administration in severe sepsis is associated with lower mortality: a retrospective analysis of the Canadian ENHANCE cohort

Richard V Hodder, Richard Hall, James A Russell, Harold N Fisher, Bobbie Lee Critical Care 2009, 13:R78 (20 May 2009)

Abstract | Full text | PDF | PubMed | Cited on BioMed Central

Review   Free Highly Accessed

Practical aspects of treatment with drotrecogin alfa (activated)

Luigi Camporota, Duncan Wyncoll Critical Care 2007, 11(Suppl 5):S7 (19 December 2007)

Abstract | Full text | PDF | PubMed | Cited on BioMed Central

Review   Free

The safety profile of drotrecogin alfa (activated)

Roberto Fumagalli, Mariano A Mignini Critical Care 2007, 11(Suppl 5):S6 (19 December 2007)

Abstract | Full text | PDF | PubMed | Cited on BioMed Central

Google Scholar: View citations

ISI Web of Science: View citations

PubMed Central: View citations